Jeffrey W Voss

US Patent:

6783756, Aug 31, 2004

Filed:

Mar 30, 1999

Appl. No.:

09/281674

Inventors:

Hermann Bujard - Heidelberg, DE
Manfred Gossen - El Cerrito CA
Jochen G. Salfeld - North Grafton MA
Jeffrey W. Voss - West Boylston MA

Assignee:

Abbott GmbH Co., KG - Wiesbaden

International Classification:

A61K 6300

US Classification:

424 9321, 514 44, 435455, 435465

Abstract:

A method for regulating expression of a tet operator-linked gene in a cell of a subject is disclosed. In one embodiment, the method involves introducing into the cell a nucleic acid molecule encoding a tetracycline-controllable transactivator (tTA), the tTA comprising a Tet repressor operably linked to a polypeptide which directly or indirectly activates transcription in eucaryotic cells; and modulating the concentration of a tetracycline, or analogue thereof, in the subject. Alternatively, in another embodiment, the method involves obtaining the cell from the subject, introducing into the cell a first nucleic acid molecule which operatively links a gene to at least one tet operator sequence, introducing into the cell a second nucleic acid molecule encoding a tTA, to form a modified cell, administering the modified cell to the subject, and modulating the concentration of a tetracycline, or analogue thereof, in the subject. The first and second nucleic acid molecule can be within a single molecule (e. g. , in the same vector) or on separate molecules.

US Patent:

7968684, Jun 28, 2011

Filed:

Nov 12, 2004

Appl. No.:

10/988360

Inventors:

Tariq Ghayur - Holliston MA, US
Boris Labkovsky - Wales MA, US
Jeffrey W. Voss - Holden MA, US
Larry Green - San Francisco CA, US
John Babcook - Vancouver, CA
Xiao-chi Jia - Los Angeles CA, US
James Wieler - Beverly MA, US
Jaspal Singh Kang - Surrey, CA
Brad Hedberg - Vancouver, CA

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07K 16/00
A61K 39/395
C12N 1/11
C12N 1/15
C12N 1/21
C12N 5/04
C12N 5/07
C12N 15/09
C12N 15/11
C12N 15/13
C12N 15/63

US Classification:

5303871, 5303873, 5303881, 53038823, 5303913, 5303917, 4241301, 4241331, 4241451, 4241781, 435 691, 4353201, 435 697, 435325, 435326, 435328, 435335, 435348, 435349, 435358, 435365, 4353651, 435410, 435419, 4352523, 43525233, 43525411, 43525421, 536 231, 536 234, 536 235, 536 2353

Abstract:

The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e. g. , in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

US Patent:

8431130, Apr 30, 2013

Filed:

Jul 26, 2010

Appl. No.:

12/843740

Inventors:

Tariq Ghayur - Holliston MA, US
Boris Labkovsky - Wales MA, US
Jeffrey W. Voss - Holden MA, US
Larry Green - San Francisco CA, US
John Babcook - Vancouver, CA
Xiao-chi Jia - Los Angeles CA, US
James Wieler - Beverly MA, US
Jaspal Singh Kang - Surrey, CA
Brad Hedberg - Vancouver, CA

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K 39/395
C07K 16/18
C07K 16/24
C12P 21/08

US Classification:

4241451, 4241301, 4241331, 4241411, 4241781, 4241811, 5303871, 5303873, 5303881, 53038823, 5303911

Abstract:

The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e. g. , in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

US Patent:

20020086426, Jul 4, 2002

Filed:

Feb 5, 2001

Appl. No.:

09/777317

Inventors:

Hermann Bujard - Heidelberg, DE
Manfred Gossen - El Cerrito CA, US
Jochen Salfeld - North Grafton MA, US
Jeffrey Voss - West Boylston MA, US

Assignee:

BASF Aktiengesellschaft - Ludwigshafen

International Classification:

C12N015/00

US Classification:

435/440000

Abstract:

A method for regulating expression of a tet operator-linked gene in a cell of a subject is disclosed. In one embodiment, the method involves introducing into the cell a nucleic acid molecule encoding a tetracycline-controllable transactivator (tTA), the tTA comprising a Tet repressor operably linked to a polypeptide which directly or indirectly activates transcription in eucaryotic cells; and modulating the concentration of a tetracycline, or analogue thereof, in the subject. Alternatively, in another embodiment, the method involves obtaining the cell from the subject, introducing into the cell a first nucleic acid molecule which operatively links a gene to at least one tet operator sequence, introducing into the cell a second nucleic acid molecule encoding a tTA, to form a modified cell, administering the modified cell to the subject, and modulating the concentration of a tetracycline, or analogue thereof, in the subject. The first and second nucleic acid molecule can be within a single molecule (e.g., in the same vector) or on separate molecules.

US Patent:

20020152487, Oct 17, 2002

Filed:

Jun 25, 2001

Appl. No.:

09/892227

Inventors:

Hermann Bujard - Heidelberg, DE
Manfred Gossen - El Cerrito CA, US
Jochen Salfeld - North Grafton MA, US
Jeffrey Voss - West Boylston MA, US

Assignee:

BASF Aktiengesellschaft

International Classification:

A01K067/027
A61K031/65

US Classification:

800/014000, 800/015000, 800/016000, 800/017000, 800/018000, 514/152000

Abstract:

Transgenic animals carrying two transgenes, the first coding for a transactivator fusion protein comprising a tet repressor and a polypeptide which directly or indirectly activates in eucaryotic cells, and the second comprising a gene operably linked to a minimal promotor operably linked to at least one tet operator sequence, are disclosed. Isolated DNA molecules (e.g., targeting vectors) for integrating a polynucleotide sequence encoding a transactivator of the invention at a predetermined location within a second target DNA molecule by homologous recombination are also disclosed. Transgenic animals having the DNA molecules of the invention integrated at a predetermined location in a chromosome by homologous recombination are also encompassed by the invention. Methods to regulate the expression of a tet operator linked-gene of interest by administering tetracycline or a tetracycline analogue to an animal of the invention are also disclosed. The regulatory system of the invention allows for conditional inactivation or modulation of expression of a gene of interest in a host cell or animal.

US Patent:

20050100965, May 12, 2005

Filed:

Nov 12, 2003

Appl. No.:

10/706689

Inventors:

Tariq Ghayur - Holliston MA, US
Boris Labkovsky - Marlborough MA, US
Jeffrey Voss - Holden MA, US
Larry Green - San Francisco CA, US
John Babcook - Vancouver, CA
Xiao-chi Jia - Los Angeles CA, US
James Wieler - Beverly MA, US
Jaspal Kang - Surrey, CA
Brad Hedberg - Vancouver, CA

International Classification:

G01N033/53
C07H021/04
C07K016/24
C12N005/06

US Classification:

435007100, 435069100, 435320100, 435335000, 530388230, 536023530

Abstract:

The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

US Patent:

20090312338, Dec 17, 2009

Filed:

Jun 9, 2009

Appl. No.:

12/481028

Inventors:

Neil Wishart - Jefferson MA, US
Maria A. Argiriadi - Wayland MA, US
David J. Calderwood - Framingham MA, US
Anna M. Ericsson - Shrewsbury MA, US
Bryan A. Fiamengo - Worcester MA, US
Kristine E. Frank - Worcester MA, US
Michael Friedman - Newton MA, US
Dawn M. George - Charlton MA, US
Eric R. Goedken - Worcester MA, US
Nathan S. Josephsohn - Boston MA, US
Biqin C. Li - Northborough MA, US
Michael J. Morytko - Framingham MA, US
Kent D. Stewart - Gurnee IL, US
Jeffrey W. Voss - Holden MA, US
Grier A. Wallace - Sterling MA, US
Lu Wang - Northborough MA, US
Kevin R. Woller - Anitoch IL, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

A61K 31/4985
C07D 487/14

US Classification:

514250, 544346

Abstract:

The invention provides a compound of Formula (I)pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

US Patent:

20110190489, Aug 4, 2011

Filed:

Dec 1, 2010

Appl. No.:

12/958291

Inventors:

Neil Wishart - Jefferson MA, US
Maria A. Argiriadi - Wayland MA, US
David J. Calderwood - Framingham MA, US
Anna M. Ericsson - Shrewsbury MA, US
Bryan R. Fiamengo - Worcester MA, US
Kristine E. Frank - Worcester MA, US
Michael Friedman - Newton MA, US
Dawn M. George - Charlton MA, US
Eric R. Goedken - Worcester MA, US
Nathan S. Josephsohn - Boston MA, US
Biqin C. Li - Northborough MA, US
Michael J. Morytko - Framingham MA, US
Kent D. Stewart - Gurnee IL, US
Jeffrey W. Voss - Holden MA, US
Grier A. Wallace - Sterling MA, US
Lu Wang - Northborough MA, US
Kevin R. Woller - Anitoch IL, US
Eric C. Breinlinger - Charlton MA, US
Kelly D. Mullen - Charlton MA, US
Gagandeep Somal - Framingham MA, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07D 413/14
C07D 471/14
C07D 487/14
C07F 9/06

US Classification:

544115, 546 82, 544346, 546 23, 544337, 544295

Abstract:

The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.